LON:HEMO Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis GBX 1.32 -0.02 (-1.49%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlines About Hemogenyx Pharmaceuticals Stock (LON:HEMO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HEMO alerts:Sign Up Key Stats Today's Range 1.30▼ 1.4050-Day Range 1.13▼ 1.7552-Week Range 1.08▼ 7.13Volume2.12 million shsAverage Volume9.05 million shsMarket Capitalization£17.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewHemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.Read More… Musk warns humanity: “Obsolete” (Ad)The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. Receive HEMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HEMO Stock News HeadlinesHemogenyx Pharmaceuticals PLC Announces Schedule for Phase I Clinical Trial OpeningOctober 30 at 8:02 PM | finance.yahoo.comHemogenyx Pharmaceuticals loss narrows amid reduced expensesSeptember 28, 2024 | lse.co.ukMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.November 2, 2024 | The Freeport Society (Ad)Hemogenyx Pharmaceuticals Plc (HEMO.L) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC - FLT3 Assay Ready for Phase I Trials at MD AndersonSeptember 9, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces CDX Development UpdateSeptember 3, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T ConferenceAugust 28, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Macrophage-Directed Therapies Summit PresentationJuly 29, 2024 | finance.yahoo.comSee More Headlines HEMO Stock Analysis - Frequently Asked Questions How have HEMO shares performed this year? Hemogenyx Pharmaceuticals' stock was trading at GBX 2.30 at the start of the year. Since then, HEMO stock has decreased by 42.4% and is now trading at GBX 1.33. View the best growth stocks for 2024 here. How were Hemogenyx Pharmaceuticals' earnings last quarter? Hemogenyx Pharmaceuticals Plc (LON:HEMO) issued its quarterly earnings results on Wednesday, September, 30th. The company reported ($0.20) EPS for the quarter. How do I buy shares of Hemogenyx Pharmaceuticals? Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Hemogenyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include 4D pharma (DDDD), genedrive (GDR), International Consolidated Airlines Group (IAG), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA). Company Calendar Last Earnings9/30/2020Today11/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:HEMO Previous SymbolLON:SILF CUSIPN/A CIKN/A Websilverfalconplc.com Phone44 79 0917 7311FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-5,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-155.97% Return on Assets-37.79% Debt Debt-to-Equity Ratio92.09 Current Ratio4.38 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,340,000,000Free FloatN/AMarket Cap£17.76 million OptionableNot Optionable Beta3.14 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (LON:HEMO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.